Literature DB >> 26074028

Uterine Artery Embolization for Adenomyosis: Percentage of Necrosis Predicts Midterm Clinical Recurrence.

Sohi H Bae1, Man Deuk Kim2, Gyoung Min Kim1, Shin Jae Lee1, Sung Il Park1, Jong Yun Won1, Do Yun Lee1.   

Abstract

PURPOSE: To evaluate the effect of degree of necrosis after uterine artery embolization (UAE) on symptom recurrence at midterm clinical follow-up in patients with adenomyosis.
MATERIALS AND METHODS: Women (N = 50) who underwent UAE for symptomatic adenomyosis were retrospectively analyzed. All patients underwent contrast-enhanced magnetic resonance (MR) imaging at baseline and 3 months after UAE and were followed clinically for at least 18 months. The type of adenomyosis was classified as focal or diffuse. The uterine volume and the percentage of necrosis after embolization were measured three-dimensionally on MR imaging. The percentage of the necrosis cutoff point for predicting recurrence was estimated. Patients were divided into 2 groups according to the cutoff point. The rate of recurrence was compared between groups, and risk factors for recurrence were identified.
RESULTS: During the follow-up period (range, 18-48 mo), symptom recurrence occurred in 12 of 50 patients. A necrosis cutoff point of 34.3% was calculated to predict recurrence (area under the curve = 0.721; 95% confidence interval [CI] = 0.577-0.839; P = .004). Patients with < 34.3% necrosis (group A, n = 12) were at a significantly higher risk of recurrence than patients with > 34.3% necrosis (group B, n = 38; hazard ratio = 7.0; 95% CI = 2.2, 22.4; P = .001). Initial uterine volume and type of adenomyosis were not associated with recurrence.
CONCLUSIONS: The percentage of necrosis in patients with adenomyosis after UAE may predict symptom recurrence at midterm follow-up. The cutoff percentage of necrosis required to predict symptom recurrence was 34.3% in this study.
Copyright © 2015 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26074028     DOI: 10.1016/j.jvir.2015.04.026

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  7 in total

Review 1.  Updates on Uterine Artery Embolization.

Authors:  Maureen P Kohi; James B Spies
Journal:  Semin Intervent Radiol       Date:  2018-04-05       Impact factor: 1.513

Review 2.  Adenomyosis - An Overview.

Authors:  Stephanie Wong; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2022-02-18       Impact factor: 1.513

3.  Outcomes in Adenomyosis Treated with Uterine Artery Embolization Are Associated with Lesion Vascularity: A Long-Term Follow-Up Study of 252 Cases.

Authors:  Jing Zhou; Li He; Ping Liu; Hui Duan; Hanze Zhang; Weili Li; Shipeng Gong; Guidong Su; Chunlin Chen
Journal:  PLoS One       Date:  2016-11-02       Impact factor: 3.240

4.  Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Adenomyosis: Protocol for the Randomized QUESTA Trial.

Authors:  Annefleur Machteld de Bruijn; Wouter Jk Hehenkamp; Paul Nm Lohle; Judith Af Huirne; Jolanda de Vries; Moniek Twisk
Journal:  JMIR Res Protoc       Date:  2018-03-01

5.  Uterine Artery Embolization for Symptomatic Adenomyosis: 7-Year Clinical Follow-up Using UFS-Qol Questionnaire.

Authors:  Annefleur M de Bruijn; Marieke Smink; Wouter J K Hehenkamp; Robbert J Nijenhuis; Albert J Smeets; Focco Boekkooi; Paul J H M Reuwer; Willem J Van Rooij; Paul N M Lohle
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-17       Impact factor: 2.740

6.  Uterine Artery Embolization for Leiomyomas and Adenomyosis: A Pictorial Essay Based on Our Experience from 1300 Cases.

Authors:  Man Deuk Kim
Journal:  Korean J Radiol       Date:  2019-10       Impact factor: 3.500

7.  Uterine Artery Embolization with Small-Sized Particles for the Treatment of Symptomatic Adenomyosis: A 42-Month Clinical Follow-Up.

Authors:  Kai Yuan; Jin Long Zhang; Jie Yu Yan; Bing Yuan; Jin Xin Fu; Yan Wang; Xue Dong Sun; Yang Guan; Feng Duan; Mao Qiang Wang
Journal:  Int J Gen Med       Date:  2021-07-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.